GVR Report cover Cancer Stem Cells Market Share, Size & Trends Report

Cancer Stem Cells Market Share, Size & Trends Analysis Report By Mode Of Action (Stem Cell based Cancer Therapy, Targeted CSCs), By Cancer Forms (Breast Cancer, Bladder Cancer), By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-2-68038-112-2
  • Number of Pages: 130
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Cancer Stem Cells Market Size & Trends

The global cancer stem cells market size was valued at USD 1.24 billion in 2022 and it is expected to grow at a CAGR of 12.09% over the forecast period. The increasing prevalence of cancer, increased R&D activities, and adoption of stem cells are some of the major factors driving the market. Currently, oncology therapeutics has entered a new era with conventional therapies such as radiotherapy, chemotherapy, & surgeries on one side and stem cell therapies on another side.

U.S. Cancer Stem Cells Market size and growth rate, 2023 - 2030

Over the past few years, stem cells have been successfully utilized in immuno-reconstitution and for blood replenishment after tumor development or treatment. Furthermore, these cells have gained significant attention among healthcare entities for their employment as tools for delivering anti-cancer agents and tissue regeneration. A considerable number of entities have reported positive outcomes of using this mode of tumor treatment. While this therapy is receiving huge success in clinical oncology, a substantial number of published studies have mentioned cancer as a “Cancer Stem Cell (CSC) disorder”. Due to the introduction of this novel concept, an enormous potential for anti-CSC therapeutics has been created.

This approach enables comprehensive investigation of essential and poorly understood clinical events in tumor initiation, propagation, relapse, and metastasis. This is considered one of the major factors responsible for increasing interest in the cancer stem cell model. There is accumulating evidence that sheds light on the existence of cancer stem cells and their role in conferring drug resistance. This further allows generating of novel targets to overcome therapeutic resistance by controlling the regulation of these cells. Hence, CSCs, as potential therapeutic targets, enable therapeutic development that effectively combat tumor progression.

There has been a constant rise in the number of cancer cases and cancer-related deaths globally over the years. For instance, according to World Health Organization (WHO), in February 2022, cancer was responsible for approximately 10 million deaths worldwide in 2020, and it is the leading cause of death worldwide. Thus, it has become very important to find an efficient treatment to regulate cancer and improve the standard of living of cancer patients. This has increased the R&D activities in the market. For instance, in January 2022, Takeda announced its plan to acquire Adaptate Biotherapeutics for the development of novel gamma delta T cell engager therapies. This can provide Takeda a leading edge to utilize delta T cell’s full potential against cancer.

Moreover, several international and global organizations are working independently and collaboratively to discover new cancer stem cell therapy advancements. For instance, in Jan 2022, Lisa Dean Moseley Foundation gave a grant of USD 9.1 million to the American Cancer Society (ACS) to form a cancer stem cell consortium. This consortium is expected to advance discoveries in cancer stem cells for increased impact on patients. However, regulatory challenges regarding the approval and usage of stem cell therapies are anticipated to inhibit the growth of the market. In addition, certain manufacturing and pharmacological issues associated with this cell therapy development are estimated to slow down the progress of the market during the forecast period.

Mode of Action Insights

The cancer stem cells market can be segmented into two models of tumor treatment based on the mode of action. The first model incorporates targeted CSCs using monoclonal antibodies, recombinant proteins, nanomaterials, and other natural compounds. The majority of commercially available drugs facilitate tumor shrinkage but do not target the root cause of tumor progression, which may further result in a relapse of tumor growth.

The targeted CSC segment accounted for a significant revenue share in 2022 and is expected to show lucrative growth over the forecast period. Increasing research on CSCs biology and their key signaling pathways, microenvironment, and surface markers are enabling the development of agents that target these aspects of CSCs to control their regulation. Of these aspects, agents targeting key pathways accounted for a major share.

Several review articles have documented the roles of these pathways in the functioning of CSCs. The second model deploys stem cells for tissue regeneration, immuno-reconstitution, and delivery of anti-cancer therapeutics. This segment is further bifurcated into autologous and allogenic cell treatment. Autologous treatments captured a significant market share in 2022 in terms of revenue.

Factors such as the advantages of autologous transplants, affordability, improved survival rate of patients, and increase in transplantation procedures are poised to contribute to the growth of the segment. However, it has been observed that many cell therapy companies are increasingly focusing on the development of allogeneic cellular therapy products. This is expected to result in noteworthy growth of this segment over the forecast period.

Cancer Forms Insights

The breast cancer segment held the largest revenue share of 24.4% in 2022, owing to its rising incidence and a relatively large number of stem cell therapeutics for this tumor type. According to WHO, breast cancer was diagnosed in around 2.3 million women in 2020 and accounted for almost 6,85,000 deaths worldwide in the same year. In addition, according to an article published by the American Cancer Society (ACS), it is estimated that in the U.S., a total of 43,250 women will pass away from breast cancer with 2,87,850 new instances of invasive breast cancer in 2022. Women over the age of 50 account for 83% of new cases of invasive breast cancer and 91% of all breast cancer-related deaths.

Global Cancer Stem Cells Market share and size, 2022

Moreover, the fact that autologous transplant has taken chemotherapy to the next level is likely to supplement the growth of the segment. Furthermore, stem cell therapies are successful in combating cardiotoxicity observed in survivors.

The lung cancer segment is expected to grow at the fastest CAGR of 14.3% over the forecast period. The growth of the segment can be attributed to the high prevalence of lung cancer. According to the American Cancer Society, in the U.S., there can be approximately 2,38,340 new lung cancer cases in 2023, causing around 1,27,070 deaths. Moreover, ongoing developments to curb the rising incidence of lung malignancy worldwide are also expected to boost the segment growth. In November 2022, Regeneron Pharmaceuticals, Inc. announced FDA approval of its Libtayo, a human monoclonal antibody, combined with chemotherapy for treating non-small cell lung cancer (NSCLC).

Regional Insights

North America accounted for the largest revenue share of 43.6% in 2022 due to the presence of a substantial number of organizations engaged in conducting R&D activities related to stem cell therapy, developed healthcare infrastructure, and the prevalence of cancers such as breast cancer, blood cancer, and lung cancer. For instance, according to United States Cancer Statistics (USCS), in 2020, almost 16,03,844 people were diagnosed with cancer, and around 6,02,347 cancer-related deaths were recorded in the U.S. Moreover, several internationally recognized hospitals and medical institutes, such as Cancer Treatment Centers of America at Midwestern Regional Medical Center, offer stem cell transplant therapies.

Cancer Stem Cells Market Trends, by Region, 2023 - 2030

Asia Pacific is expected to grow at the fastest CAGR of 16.7% over the forecast period owing to the rise in cancer cases in the region. According to the GLOBCON 2020, around 4.5 million people were diagnosed with cancer in China. The presence of several organizations in the region that focus on the R&D of stem cells and funding agencies providing grants to research communities to accelerate their scientific research on cancer stem cells in Asian countries are also expected to propel the regional growth of the cancer stem cell market. For instance, according to an article published by South China Morning Post Publishers Ltd. in September 2022, scientists at the Chines Academy of Sciences’ Key Laboratory of RNA Biology have successfully developed nanoparticles to target and eliminate cancer stem cells. The experiment was said to be successful on laboratory rats.

Key Companies & Market Share Insights

In order to keep pace with the growing popularity of stem cell therapy in clinical oncology, these firms are undertaking various endeavors to stay competitive. Strategic alliances, facility expansion, and broadening product pipelines are key initiatives these participants undertake. For instance, in April 2023, Gamida Cell received the U.S. Food and Drugs Administration (FDA) approval for their allogeneic cell therapy Omisirge. This is expected to increase stem cell transplant access and improve patient outcomes.

In January 2023, First Light Acquisition Group and Calidi Biotherapeutics, Inc. announced their merger to create a clinical-stage biotechnology company to develop oncolytic virotherapy using a stem cell-based cancer treatment delivery platform. In May 2022, Gilead and Dragonfly announced their research collaboration to advance natural killer cell engagers in oncology. Under this agreement, Gilead received a worldwide license from Dragonfly for their 5T4 targeting immunotherapy program DF7001. Some of the prominent players in the global cancer stem cells market include:

  • Thermo Fisher Scientific, Inc.

  • AbbVie, Inc.

  • Merck KGaA

  • Bionomics

  • Lonza

  • Stemline Therapeutics, Inc.

  • Miltenyi Biotec

  • PromoCell GmbH

  • MacroGenics, Inc.

  • OncoMed Pharmaceuticals, Inc.

  • FUJIFILM Irvine Scientific

  • STEMCELL Technologies.

  • Sino Biological, Inc.

  • Lineage Cell Therapeutics, Inc.

Cancer Stem Cells Market Report Scope

Report Attribute


Market size value in 2023

USD 1.4 billion

Revenue forecast in 2030

USD 3.1 billion

Growth rate

CAGR of 12.09% from 2023 to 2030

Base year for estimation


Historical data

2018 - 2021

Forecast period

2023 - 2030

Report updated

October 2023

Quantitative units

Revenue in USD million and CAGR from 2023 to 2030

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

Segments covered

Mode of action, cancer forms, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait;

Key companies profiled

Thermo Fisher Scientific, Inc.; AbbVie, Inc.; Merck KGaA; Bionomics; Lonza; Stemline Therapeutics, Inc.; Miltenyi Biotec; PromoCell GmbH; MacroGenics, Inc.; FUJIFILM Irvine Scientific; STEMCELL Technologies.; Sino Biological, Inc.; Lineage Cell Therapeutics, Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Cancer Stem Cells Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global cancer stem cells market report on the basis of mode of action, cancer forms, and region:

Global Cancer Stem Cells Market Report Segmentation

  • Mode of Action Outlook (Revenue, USD Million, 2018 - 2030)

    • Targeted Cancerous Stem Cells (CSCs)

      • By Anti-CSC Therapeutics

        • Pathway Inhibitors

          • WNT Signaling Pathway

          • Hedgehog Signaling Pathway

          • Notch Signaling Pathway

          • Others

        • Surface Marker-based

        • Immuno-evasion & Targeting Tumor Microenvironment

        • Nanoparticle-based Therapies

        • Others

      • Products

        • Cell-Culturing

        • Cell-Separation

        • Cell Analysis

        • Molecular Analysis

        • Others

    • Stem Cell-based Cancer Therapy

      • Autologous SC Transplant

      • Allogeneic SC Transplant

  • Cancer Forms Outlook (Revenue, USD Million, 2018 - 2030)

    • Breast cancer

    • Blood cancer

    • Lung cancer

    • Brain cancer

    • Colorectal cancer

    • Pancreatic cancer

    • Bladder cancer

    • Liver cancer

    • Others cancer

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Sweden

      • Norway

      • Denmark

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa

      • Saudi Arabia

      • South Africa

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.